Fogarty Institute for Innovation
Andrew Cleeland is a seasoned executive with 30 years in the medical device industry in both the private and public-sectors.
Prior to joining the FII, he was Vice President and General Manager of Medtronic’s (MDT:NYSE) Transcatheter Mitral Valve business following its 2015 acquisition of Twelve Inc., where he was president and CEO. Prior to Twelve, he was president and CEO of Ardian Inc., the pioneer of renal denervation for hypertension, heart failure and other associated disorders, which was also acquired by Medtronic in 2011. Together these two acquisitions totaled $1.5B.
Andrew began his career with the Australian Therapeutic Goods Administration, progressed to large med tech companies in Telectronics Pacing Systems and Baxter Healthcare (BAX:NYSE), then onto the Silicon Valley start-up space working with Radiant Medical, Ardian and Twelve.
He is also currently Vice Chairman of The Foundry, the premier medical device incubator based in Menlo Park, California and serves as a Director for two venture-funded companies nVision Medical and Saluda Medical.
Andrew has received numerous awards and honors, and is a frequent guest lecturer at Stanford University. He is passionate about healthcare and a champion of innovators and innovation in the med tech field. He holds a Bachelor of Applied Science (Biophysics) from the Swinburne Institute of Technology.